Ask AI
ProCE Banner Activity

Prognostic Value of ctDNA-MRD by PhasED-Seq at the End of First-line Treatment for DLBCL in a National Cohort

Conference Coverage
Slideset

In this prospective study, ctDNA-based MRD analysis demonstrated prognostic value in patients with newly diagnosed DLBCL who received frontline therapy with curative intent.

Released: June 09, 2025

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation